PECAM1 and depressive symptom measurement: In the current study, we demonstrated that two biomarkers, ICAM-1 and PECAM-1, were significantly higher in the serum of patients associated with cognitive dysfunction, depression, vestibulocerebellar ataxia, and in the group of patients following chemotherapy.